The Stanislas Cohort is a monocentric familial longitudinal cohort originally comprised of 1006 families consisting of two parents and at least two biological children and deemed healthy, recruited in 1993-1995 at the Centre for Preventive Medicine of Nancy. This cohort was established with the primary objective of investigating gene-gene and gene-environment interactions in the field of cardiovascular diseases. The 5th visit of the STANISLAS Cohort will allow a better evaluation of the cardiovascular ageing of the population and the transition toward cardiovascular or renal diseases in relation with their genetic profile and environment.
The main objective of the STANISLAS cohort is to identify the factors associated with cardiovascular aging (assessed through the study of the degradation of morphological and functional parameters of the heart and vascular systems). Data (clinical, biological, morphological, genetic and lifestyle) from previous visits (the first having been initiated in the mid-1990s) will be considered as exposure and / or adjustment variables. The exposure variables of interest will be: * The components of metabolic syndrome (MS), * Genetic determinants, through an approach of family segregation and candidate genes, * Multi-omic biomarkers analyzed from the biological collection of the first assessments of the cohort * Food intake, nutrition and eating behavior The secondary objectives are * Identify the factors associated with a degradation of renal parameters (renal function and proteinuria). * Identify the factors associated with a degradation of metabolic parameters. * To assess the association between SARS-CoV-2 infection (questionnaire and serological approach) and cardiovascular and renal parameters * Identify factors associated with the occurrence of clinical cardiovascular events. * Association between Covid 19 events and general disabling symptoms * Complete the cohort's biological collection for future biomarker assays related to previous objectives
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
3,000
Blood and urine samples
Blood samples
Echocardiography, Lung ultrasound, pulse wave velocity, carotid stiffness and thickness, Central and peripheral blood pressure, carotid pulse pressure, abdominal aorta ultrasound, jugular vein ultrasound, liver elastography (Optional).
Food frequency questionnaires, ''Dutch eating behaviour questionnaire'' and dietary supplement questionnaire
Measurement of height, weight, abdominal circumference, hip circumference, arm circumference
Systolic pressure index measurement
Heart rate measurements, blood pressure measurements, orthostatic BP measurements
Blood pressure measurements by "unattended BP" monitor over 5 min
Electrocardiogram
EVALOBS scale and compliance questionnaire
For the first 100 patients willing to participate
For the first 100 patients willing to participate. For biobank constitution and measurement of microalbuminuria, creatininuria, osmolarity, natriuresis, kaliuresis, urea, proteinuria and urine dipstick
Collection of socio-demographic data such as age, level of education, profession, household income, smoking status, physical activity, perception of health, prematurity, height and weight at birth, family and personal history especially cardiovascular (history of stroke, myocardial infarction, heart failure, current pathologies, drugs, tobacco...)
Women specific questionnaire
Women specific questionnaire
Determination of NYHA class.
Assessment of anxiety
sleep quality assessment
Patient's evaluation of cardiovascular risk factors by the health system
Assessment of eating behaviors
Assessement of eating habit to create a consumer profile
Evaluation od food supplements intake
SARS-CoV-2 Infection Questionnaire
Carbon monoxyde analysis in expired air
Capillary sampling for pollutant analysis (Optional)
CHRU de Nancy
Vandœuvre-lès-Nancy, Lorraine, France
RECRUITINGIndexed left ventricular mass measured by echocardiography
Time frame: Baseline
Left ventricular volume measured by echocardiography
Time frame: Baseline
Tissue doppler imaging e' wave measured by echocardiography
Time frame: Baseline
Ratio E/e' measured by echocardiography
Time frame: Baseline
Left atrial volume measured by echocardiography
Time frame: Baseline
Pulmonary congestion evaluated by lung ultrasound
Time frame: Baseline
Pulse wave velocity measured by Sphygmocor and Complior Analyse
Time frame: Baseline
Carotid intima media thickness measured by echotracking
Time frame: Baseline
Central blood pressure
Time frame: Baseline
Estimation of the glomerular filtration rate (CKD-EPI formula)
Composite endpoint of degradation of renal function (With outcome 11)
Time frame: Baseline
Proteinuria (on sample)
Composite endpoint of degradation of renal function (With outcome 10)
Time frame: Baseline
Blood glucose
Composite endpoint of degradation of metabolic parameters (With outcome 13 and 14)
Time frame: Baseline
Change in HbA1C
Composite endpoint of degradation of metabolic parameters (With outcome 12 and 14)
Time frame: Baseline
Change in lipid parameters (LDL and HDL cholesterol)
Composite endpoint of degradation of metabolic parameters (With outcome 12 and 13)
Time frame: Baseline
Occurrence of the following clinical CV events: Hospitalization for HF, HF not requiring hospitalization, Atrial fibrillation, Acute coronary syndrome, Coronary artery disease, Hypertension (requiring introduction of drug treatment), Stroke
Time frame: Baseline
General symptoms persisting beyond 8 weeks after SARS-CoV-2 infection such as: disabling asthenia, disabling dyspnea, cardiothoracic signs, arthromyalgia, neurocognitive disorders or anosmia
Time frame: Baseline
Results of future relevant biomarker assays
Biomarkers on the cardiovascular field, measured on biological collection and dependant on the progress of knowledge and technology
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.